EP1218347A1 - Pyrazoloanthrone et derives associes en tant qu'inhibiteurs de kinase n-terminale jun (jnk), et leurs compositions - Google Patents
Pyrazoloanthrone et derives associes en tant qu'inhibiteurs de kinase n-terminale jun (jnk), et leurs compositionsInfo
- Publication number
- EP1218347A1 EP1218347A1 EP00955709A EP00955709A EP1218347A1 EP 1218347 A1 EP1218347 A1 EP 1218347A1 EP 00955709 A EP00955709 A EP 00955709A EP 00955709 A EP00955709 A EP 00955709A EP 1218347 A1 EP1218347 A1 EP 1218347A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- alkyl
- jnk
- pyrazol
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37823499A | 1999-08-19 | 1999-08-19 | |
US378234 | 1999-08-19 | ||
US09/642,557 US7119114B1 (en) | 1999-08-19 | 2000-08-18 | Pyrazoloanthrone and derivatives thereof as JNK inhibitors and compositions and methods related thereto |
PCT/US2000/022727 WO2001012609A1 (fr) | 1999-08-19 | 2000-08-19 | Pyrazoloanthrone et derives associes en tant qu'inhibiteurs de kinase n-terminale jun (jnk), et leurs compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1218347A1 true EP1218347A1 (fr) | 2002-07-03 |
Family
ID=23492297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00955709A Withdrawn EP1218347A1 (fr) | 1999-08-19 | 2000-08-19 | Pyrazoloanthrone et derives associes en tant qu'inhibiteurs de kinase n-terminale jun (jnk), et leurs compositions |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1218347A1 (fr) |
JP (1) | JP2003532626A (fr) |
KR (2) | KR100835700B1 (fr) |
CN (1) | CN1304375C (fr) |
AU (1) | AU780306B2 (fr) |
CA (1) | CA2383268A1 (fr) |
HK (1) | HK1053107A1 (fr) |
NZ (1) | NZ517578A (fr) |
WO (1) | WO2001012609A1 (fr) |
ZA (1) | ZA200201312B (fr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040072888A1 (en) | 1999-08-19 | 2004-04-15 | Bennett Brydon L. | Methods for treating inflammatory conditions or inhibiting JNK |
US7119114B1 (en) | 1999-08-19 | 2006-10-10 | Signal Pharmaceuticals, Llc | Pyrazoloanthrone and derivatives thereof as JNK inhibitors and compositions and methods related thereto |
US7429599B2 (en) * | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
GB0108770D0 (en) | 2001-04-06 | 2001-05-30 | Eisai London Res Lab Ltd | Inhibitors |
DE60234510D1 (de) | 2001-04-16 | 2010-01-07 | Eisai R&D Man Co Ltd | 1h-indazolverbindungen die jnk hemmen |
US7018999B2 (en) | 2001-05-16 | 2006-03-28 | Cephalon, Inc. | Methods for the treatment and prevention of pain |
US7683078B2 (en) | 2001-07-23 | 2010-03-23 | Laboratoires Serono S.A. | Arylsulfonamide derivatives as C-Jun-N-Terminal Kinases (JNK's) inhibitors |
JP4388376B2 (ja) | 2002-02-28 | 2009-12-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 新規な縮合環インダゾール化合物 |
WO2003082869A1 (fr) | 2002-03-28 | 2003-10-09 | Eisai Co., Ltd. | Azaindoles en tant qu'inhibiteurs de kinases a terminaison c-jun n |
JP2005534618A (ja) | 2002-03-28 | 2005-11-17 | エーザイ株式会社 | 神経変性疾患用の、c−junn−末端キナーゼ阻害剤としての7−アザインドール |
BR0309009A (pt) * | 2002-04-05 | 2005-03-22 | Boehringer Ingelheim Pharma | Método para o tratamento de hipersecreção de muco |
WO2003102151A2 (fr) * | 2002-05-30 | 2003-12-11 | Celgene Corporation | Procedes d'utilisation d'inhibiteurs de jnk ou de mkk en vue de moduler la differenciation cellulaire et de traiter des troubles myeloproliferatifs et des syndromes myelodysplasiques |
JP4414881B2 (ja) | 2002-05-31 | 2010-02-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾール化合物およびこれを含んでなる医薬組成物 |
US20040087642A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain |
US20040092568A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods for the treatment, prevention and management of macular degeneration |
US20050019366A1 (en) * | 2002-12-31 | 2005-01-27 | Zeldis Jerome B. | Drug-coated stents and methods of use therefor |
GB0305142D0 (en) | 2003-03-06 | 2003-04-09 | Eisai London Res Lab Ltd | Synthesis |
EP1628975A2 (fr) | 2003-05-16 | 2006-03-01 | Eisai Co., Ltd. | Inhibiteurs des jnk |
CN1901903A (zh) * | 2003-11-06 | 2007-01-24 | 细胞基因公司 | 用于治疗和控制石棉相关性疾病和病症的包含jnk抑制剂的组合物以及其使用方法 |
WO2005074921A1 (fr) * | 2004-02-09 | 2005-08-18 | University Of Zurich | Traitement de l'atherosclerose |
MX2007001155A (es) * | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
US7803824B2 (en) | 2004-10-29 | 2010-09-28 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases to treat glaucoma |
US20060094753A1 (en) * | 2004-10-29 | 2006-05-04 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases |
AU2005309732A1 (en) * | 2004-11-23 | 2006-06-01 | Celgene Corporation | JNK inhibitors for treatment of CNS injury |
US20060223807A1 (en) | 2005-03-29 | 2006-10-05 | University Of Massachusetts Medical School, A Massachusetts Corporation | Therapeutic methods for type I diabetes |
KR20080044836A (ko) | 2005-07-15 | 2008-05-21 | 라보라뚜와르 세로노 에스. 에이. | 자궁내막증 치료용 jnk 억제제 |
BRPI0613042A2 (pt) | 2005-07-15 | 2010-12-14 | Serono Lab | inibidores de jnk para o tratamento de endometriose |
GB0516156D0 (en) | 2005-08-05 | 2005-09-14 | Eisai London Res Lab Ltd | JNK inhibitors |
KR20080097190A (ko) | 2005-12-29 | 2008-11-04 | 안트로제네시스 코포레이션 | 태반 줄기세포의 수집과 보존을 위한 개선된 조성물과 이조성물의 이용 방법 |
KR102484810B1 (ko) | 2016-05-25 | 2023-01-05 | (주)아모레퍼시픽 | 피부 미백용 조성물 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH538528A (de) * | 1968-11-07 | 1973-06-30 | Hoechst Ag | Verfahren zur Herstellung von faserreaktiven Farbstoffen |
DE2200127A1 (de) * | 1972-01-03 | 1973-07-12 | Basf Ag | Verfahren zur herstellung von dichlor1,1'-dianthrachinonylen und deren derivaten |
DE2558813C2 (de) * | 1975-12-27 | 1984-10-31 | Hoechst Ag, 6230 Frankfurt | Lichtempfindliches Gemisch mit synergistischem Initiatorsystem |
US4198518A (en) * | 1977-09-02 | 1980-04-15 | Ciba-Geigy Corporation | Process for the production of 3-substituted pyrazolanthrones |
-
2000
- 2000-08-19 KR KR1020027002168A patent/KR100835700B1/ko not_active IP Right Cessation
- 2000-08-19 CA CA002383268A patent/CA2383268A1/fr not_active Abandoned
- 2000-08-19 KR KR1020087006016A patent/KR20080028516A/ko not_active Application Discontinuation
- 2000-08-19 JP JP2001517507A patent/JP2003532626A/ja active Pending
- 2000-08-19 NZ NZ517578A patent/NZ517578A/en unknown
- 2000-08-19 AU AU67863/00A patent/AU780306B2/en not_active Ceased
- 2000-08-19 EP EP00955709A patent/EP1218347A1/fr not_active Withdrawn
- 2000-08-19 CN CNB008143870A patent/CN1304375C/zh not_active Expired - Fee Related
- 2000-08-19 WO PCT/US2000/022727 patent/WO2001012609A1/fr active IP Right Grant
-
2002
- 2002-02-15 ZA ZA200201312A patent/ZA200201312B/en unknown
- 2002-12-23 HK HK02109283.5A patent/HK1053107A1/zh unknown
Non-Patent Citations (1)
Title |
---|
See references of WO0112609A1 * |
Also Published As
Publication number | Publication date |
---|---|
KR20020038733A (ko) | 2002-05-23 |
AU780306B2 (en) | 2005-03-17 |
KR20080028516A (ko) | 2008-03-31 |
CN1304375C (zh) | 2007-03-14 |
HK1053107A1 (zh) | 2003-10-10 |
CA2383268A1 (fr) | 2001-02-22 |
WO2001012609A1 (fr) | 2001-02-22 |
CN1379763A (zh) | 2002-11-13 |
NZ517578A (en) | 2004-02-27 |
JP2003532626A (ja) | 2003-11-05 |
ZA200201312B (en) | 2003-02-17 |
KR100835700B1 (ko) | 2008-06-09 |
AU6786300A (en) | 2001-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU780306B2 (en) | Pyrazoloanthrone and derivatives thereof as JNK inhibitors and their compositions | |
AU2002220195B2 (en) | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | |
JP5739527B2 (ja) | RhoキナーゼインヒビターとしてのN−環式−3−(環状カルボニルアミノメチル)ベンズアミド誘導体 | |
US7335676B2 (en) | Methods for treating inflammatory conditions or inhibiting JNK | |
CA2659696C (fr) | Derives de 6-1h imidazoquinazoline et de quinoleine, nouveaux puissants analgesiques et agents anti-inflammatoires | |
US8227480B2 (en) | Indazole derivative having spiro ring structure in side chain | |
US20030073732A1 (en) | Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related thereto | |
KR20060025131A (ko) | Jnk 억제에 의한 염증성 증상 또는 대사성 증상의 치료또는 예방 방법 | |
EP1349840A2 (fr) | Derives d'anilinopyrimidine utilises comme inhibiteurs du chemin de la kinase de n terminal (jnk) et compositions et techniques associees | |
AU2002227214A1 (en) | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto | |
EP2128156A1 (fr) | Nouveaux dérivés d'oxadiazole et dérivés de thidiazole ayant une activité inhibant la néovascularisation | |
WO2007027842A1 (fr) | Derives d'anilinopyrazole utilises dans le traitement du diabete | |
EP1458712A2 (fr) | Composes | |
US7119114B1 (en) | Pyrazoloanthrone and derivatives thereof as JNK inhibitors and compositions and methods related thereto | |
JP2008543968A (ja) | 新規なピラゾロピリミジノン誘導体 | |
CA2446051A1 (fr) | Derives de phthalazine avec activite inhibant l'angiogenese | |
AU2002251936B2 (en) | Anthrone derivatives and their use as ink inhibitors | |
Duffy et al. | The Discovery of VX-745: A Novel and Selective p38r Kinase Inhibitor | |
AU2002251936A1 (en) | Anthrone derivatives and their use as ink inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020318 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
17Q | First examination report despatched |
Effective date: 20021220 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SATOH, YOSHITAKA Inventor name: O'LEARY, EOIN, C. Inventor name: MURRAY, BRION, W. Inventor name: MANNING, ANTHONY, M. Inventor name: BHAGWAT, SHRIPAD, S. Inventor name: BENNETT, BRYDON, L. |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SATOH, YOSHITAKA Inventor name: O'LEARY, EOIN, C. Inventor name: MURRAY, BRION, W. Inventor name: MANNING, ANTHONY, M. Inventor name: BHAGWAT, SHRIPAD, S. Inventor name: BENNETT, BRYDON, L. |
|
17Q | First examination report despatched |
Effective date: 20021220 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20081031 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1053107 Country of ref document: HK |